Antifungal Pharmacokinetics and Pharmacodynamics
Open accessThe DOI matches its Crossref record; 244 of the 250 references it cites were found in a registry or an index.
Abstract
Successful treatment of infectious diseases requires choice of the most suitable antimicrobial agent, comprising consideration of drug pharmacokinetics (PK), including penetration into infection site, pathogen susceptibility, optimal route of drug administration, drug dose, frequency of administration, duration of therapy, and drug toxicity. Antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) studies consider these variables and have been useful in drug development, optimizing dosing regimens, determining susceptibility breakpoints, and limiting toxicity of antifungal therapy. Here the concepts of antifungal PK/PD studies are reviewed, with emphasis on methodology and application. The initial sections of this review focus on principles and methodology. Then the pharmacodynamics of each major antifungal drug class (polyenes, flucytosine, azoles, and echinocandins) is discussed. Finally, the review discusses novel areas of pharmacodynamic investigation in the study and application of combination therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This has been attributed to non-mycologic causes such as host factors, immune status, and/or pharmacologic issues8.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [8]
In the citing paper
“it leaves the polyene amphotericin B, which is toxic8, as the only treatment option for these infections.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [8]
Citations
Cites
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660 · cited 2×
“…of cryptococcal meningitis 14 Cite this article as Cold Spring Harb Perspect Med 2015;5:a019653 w w w .p er sp ec ti ve si n m ed ic in e. o rg (Perfect et al. 2010), and, until recently, although clinical efficacy was clear with this strategy, formal PK/PD studies were lacking for this…”
BackgroundRex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,556
Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“From a pharmacodynamic (PD) perspective, PK measures represent drug exposure with respect to the host, for example, translating a dose (i.e., mg/kg) to a drug exposure (e.g., area under the concentration curve, or AUC) (Drusano 2004).”
BackgroundPascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793 · cited 1×
“Study from two phase 3 clinical trials of micafungin use in patients with candidemia or invasive candidiasis was recently used for PK/PD analysis (Andes et al. 2012).”
Self-citationAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Walsh, T. J., Raad, I., Patterson, T. F., Chandrasekar, P., Donowitz, G. R., Graybill, R., Greene, R. E., Hachem, R., Hadley, S., Herbrecht, R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/508774 · Cited by 752
Cited by
Items 101–139 of 139
Lepak, A. J., Bhavnani, S. M., Castanheira, M., Rubino, C. M., Hammel, J., Safir, M. C., Massey, J., Hartman, W., Ambrose, P. G., & Andes, D. R. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01643-25 · Cited by 2
Self-citationHamon, A., Bournaud, L. F., Benaboud, S., Coriat, R., Djibrine, A., Fernández, A., Morand, E., Rouges, C., Blez, D., Canouï, É., et al. (2026) · Journal of Infection · doi:10.1016/j.jinf.2026.106734 · Cited by 2
Kroustali, V., Pournaras, S., & Meletiadis, J. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag182 · Cited by 2
“The PK/PD targets of 50% Emax and net stasis were proposed as clinically relevant for azoles and echinocandins, respectively [35].”
Feng, Y., Zhen, C., Li, W., Whiteway, M. S., Fang, X., Shen, X., Jiang, Y., & Lu, H. (2026) · Microbiological Research · doi:10.1016/j.micres.2026.128595 · Cited by 4
Perlin, D. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_22 · Cited by 2
Wirth, F., Staudt, K. J., de Araújo, B. V., & Ishida, K. (2022) · Future Microbiology · doi:10.2217/fmb-2021-0291 · Cited by 2
Essien, F. A., Westbrook, M., Wolfley, G., Patterson, S. B., & Carrol, M. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221102784 · Cited by 2
Nanomedicine for the Treatment of Vaginal Candidiasis
Vartak, R., Menon, S., Patki, M., Liang, X., Billack, B., & Patel, K. R. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-39020-3_5 · Cited by 4
Sistemas de liberação para anfotericina B e miltefosina no tratamento das candidíases.
de Bastiani, F. W. M. D. S. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2019.tde-28012019-153532 · Cited by 3
Gharibi, S. (2018) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 2
Waykar, R. G., & Kumarapillai, S. (2024) · International Journal of Pharmaceutical Quality Assurance · doi:10.25258/ijpqa.15.3.33 · Cited by 3
Nouwar, R. E., Lapique, E. L., Eynden, F. V., Martiny, D., Remmelink, M., Roussoulieres, A. L. S., & Hites, M. (2025) · Microorganisms · doi:10.3390/microorganisms13030580 · Cited by 2
“Higher-than-usual doses of echinocandins are thought to be more effective in difficult-to-treat forms of candidiasis, including endocarditis [7].”
Single‐Dose, Intravenous, and Oral Pharmacokinetics of Isavuconazole in Dogs
Kuo, Y., Zhong, L., Forsythe, L. R. E., & Reinhart, J. M. (2025) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.13510 · Cited by 1
“Definitive pharmacodynamic targets have not been established for isavuconazole, but for other azoles, an AUC/MIC ratio appears to be the best predictor of treatment success (Lepak and Andes 2014).”
Chen, B., Chen, Y., Chen, M., Mao, Y., Huang, Y., Zhou, L., Wu, W., Li, X., Wu, X., Cheng, Y., et al. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00519-25 · Cited by 1
Rathod, S. K., Manna, S. K., Tripathi, G., Das, B. K., Sarkar, D. J., Das, N., Kumar, S., Panda, S. K., Nadella, R. K., & Patil, P. K. (2026) · Veterinary Research Communications · doi:10.1007/s11259-026-11145-z · Cited by 1
Vanzolini, T., Fiori, V., & Magnani, M. (2026) · npj Antimicrobials and Resistance · doi:10.1038/s44259-026-00198-4 · Cited by 1
Wang, Y., Zhao, J., Jiang, S., Yao, Y., & Wen, H. (2020) · Open Journal of Preventive Medicine · doi:10.4236/ojpm.2020.106009 · Cited by 1
“is fAUC24h/MIC = 10 [16], Free drug fraction f is 1%.”
BackgroundPharmacokinetics and Pharmacodynamics of Antifungal Agents in Neonates and Children
Antachopoulos, C., & Roilides, E. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00402-6 · Cited by 2
Antifungal Therapy in Rhino-Orbito-Cerebral Mucormycosis (ROCM)
Soman, R. N., & Rege, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-9729-6_15 · Cited by 1
Schoenenberger-Arnaiz, J. A., Eroles, A. A., Bonastre, P. T., Morales-Portillo, A., & Cano-Marron, M. (2021) · Biomedical Research and Clinical Practice · doi:10.15761/brcp.1000222 · Cited by 1
Optimisation du traitement préventif et curatif de la mucormycose pulmonaire
Brunet, K. (2020) · theses.fr (ABES) · doi:10.70675/1367c1e7zd412z4f2ez9be3zb15a2d64bb30 · Cited by 2
Matsuno, V. K. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.9.2021.tde-09062022-111717
Hu, J., Wang, Y., Zhu, X., Yu, X., & Zhu, X. (2022) · Open Journal of Pediatrics · doi:10.4236/ojped.2022.124072
A new PK/PD target for assessing efficacy of micafungin against Candida parapsilosis
Beredaki, M.-I., Pournaras, S., & Meletiadis, J. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad360
Pharmacodynamics of Antimicrobials
Woodward, A. P., & Whittem, T. (2024) · Wiley eBooks · doi:10.1002/9781119654629.ch5
Waykar, R. G., & Kumarapillai, S. (2025) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/zm6uc
Antifungal Agents and Therapeutic Approaches in the Treatment of Invasive Fungal Infections
Choudhary, P., Punia, A., Kumari, S., & Chhillar, A. K. (2025) · Current Bioactive Compounds · doi:10.2174/0115734072368372250203055808
Principles of antimicrobial use in the intensive care unit
Ulldemolins, M., Roberts, J. A., & Lipman, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11611-7.00020-7
Antifungal interventions and clinical outcomes: A review
Simran, S., Gaba, P., Sharma, N., & Singh, J. (2026) · Scripta Medica · doi:10.5937/scriptamed57-58699
Bronson, E., Greenebaum, A., Visser, M., Mangus, L. M., Barrett, K., & Boothe, D. M. (2026) · Journal of Zoological and Botanical Gardens · doi:10.3390/jzbg7020020
“The triazole antifungals have demonstrated a prolonged post-antifungal effect with area under the curve to MIC (AUC/MIC) being the optimal predictive index of efficacy [7].”
Mahmood, D., & Salih, S. H. (2026) · passer · doi:10.24271/psr.2026.577714.2658
“The observed antifungal effects vary by population and depend on concentration "Figure 16" [52] .”
Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives
Al‐Zoubi, R. M., Farhan, A., Hanbali, B., Al-Zoubi, S. R., Al-Zoubi, Y. R., Shkoor, M., Alkharraz, L. M., Agouni, A., & Al-Jabiry, A. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119194
Therapeutic Failure in Invasive Fungal Infections: Beyond Antifungal Resistance—A Narrative Review
Rivas-Pinedo, P., & Oñate, J. (2026) · Journal of Fungi · doi:10.3390/jof12080596 · Cited by 1
Constanta, P. D., Cicalău, G. I. P., Maghiar, L., Șipoș, L. R., Huniadi, A. C., Bodog, R. F., Bodog, T. M., Beiușanu, C., Bereteu-Costa, A.-D., Nagy, C., et al. (2026) · Journal of Fungi · doi:10.3390/jof12100722
“…broad dose range is a stated requirement before a natural product is taken further [67]; the therapeutic index expresses the same relationship at the level of exposure in humans [68]; and antifungal pharmacokinetic–pharmacodynamic indices relate drug exposure to the MIC for systemic therapy [69].”
Rezafungin: ทางเลือกใหม่สำหรับรักษาการติดเชื้อแคนดิดาในกระแสเลือดและการติดเชื้อแคนดิดาแบบรุกราน
Sawekkulchol, S. (2024) · Thai Journal of Hospital Pharmacy
Kroustali, V., Pournaras, S., & Meletiadis, J. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag509
Emerging Trends in Antifungal Treatment: Role of Gels, Natural Products, and Innovative Targets
Kalhansh, A., Tomar, S., & Sharma, R. B. (2026) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v16i10.8065
Rhijn, N. V., White, P. L., & Rautemaa‐Richardson, R. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag231
Metadata
- Authors
- Lepak, A. J., & Andes, D. R.
- Affiliations
- University of Wisconsin–Madison (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-11-10
- Volume
- 5
- Issue
- 5
- Pages
- a019653-a019653
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC4448584
- OpenAlex
- W2106743979
- Cited by
- 134
- References
- 250
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 14 · 2023: 19 · 2022: 13 · 2021: 13 · 2020: 17 · 2019: 13 · 2018: 5 · 2017: 8 · 2016: 2 · 2015: 3
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal agents, pharmacokinetics, pharmacodynamics, pharmacokinetic-pharmacodynamic modeling, polyenes, 5-fluorocytosine, azoles, echinocandins, dosing regimen, susceptibility breakpoints, combination antifungal therapy, drug toxicity
- MeSH terms
- Animals, Antifungal Agents, Disease Models, Animal, Flucytosine, Humans, Mycoses, Polyenes, Rabbits, Triazoles, Mice, Rats, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.